Bid Price | 4.30p | High Price | 4.60p |
---|
Ask Price | 4.60p | Low Price | 4.60p |
---|
Open Price | 4.45p | Spread | 6.52% |
---|
Prev Close | 4.45p | Volume | 22 |
---|
Fusion Antibodies PLC Historic Prices
Date | Open | High | Low | Close | Volume |
---|
Sep 25, 2024 | 4.05 | 4.90 | 4.00 | 4.45 | 8,230,430 |
Sep 24, 2024 | 3.25 | 4.29 | 3.00 | 4.05 | 5,215,765 |
Sep 23, 2024 | 3.25 | 3.50 | 3.16 | 3.25 | 159,933 |
Sep 20, 2024 | 3.25 | 3.50 | 3.00 | 3.25 | 3,539 |
Sep 19, 2024 | 3.25 | 3.50 | 3.10 | 3.25 | 416,258 |
More Fusion Antibodies PLC Historic Prices >Fusion Antibodies PLC Information
Name | Fusion Antibodies PLC | Index | FTSE AIM All Share |
---|
ISIN | GB00BDQZGK16 | Epic | FAB |
---|
Type | Equity | Currency | GBX |
---|
Record Status | Active | Trading Segment | ASQ1 |
---|
Industry | Biotechnology | Sector | Healthcare |
---|
EMS | 10,000 | Trading Status | Regular Trading |
---|
Shares in Issue | 95.37 m | Prev Close | 4.45p |
---|
PE Ratio | | Market Cap | £4.39 m |
---|
Div Yield | 0 | Div per Share | £NaN |
---|
EPS | -£0.02 | Div Cover | NaN |
---|
PEG | n/a | EPS Growth (%) | 0.00 |
---|
ROCE | -0.520228 | DPS Growth (%) | 0 |
---|
Current Ratio | 3.873288 | Quick Ratio | 3.006849 |
---|
Fusion Antibodies PLC Director Deals
Declared | Type | Director | Pos. | Volume / Price | Value |
---|
09/09/24 | BUY | Richard Buick | ED | 94,825 @ £0.03 | £3,106.00 |
05/09/24 | BUY | Adrian Kinkaid | CEO | 120,000 @ £0.03 | £3,804.00 |
22/07/24 | BUY | Simon Douglas | CH | 150,000 @ £0.03 | £4,815.00 |
04/12/23 | BUY | Simon Douglas | CH | 100,565 @ £0.05 | £4,988.00 |
04/12/23 | BUY | Adrian Kinkaid | CEO | 101,847 @ £0.05 | £4,991.00 |
12/06/23 | BUY | Richard Buick | ED | 68,750 @ £0.07 | £4,950.00 |
24/05/23 | PLAC | Colin Walsh | NED | 600,000 @ £0.05 | £30,000.00 |
24/05/23 | PLAC | Simon Douglas | CH | 200,000 @ £0.05 | £10,000.00 |
24/05/23 | PLAC | Sonya Ferguson | RES | 400,000 @ £0.05 | £20,000.00 |
24/05/23 | PLAC | Adrian Kinkaid | CEO | 140,000 @ £0.05 | £7,000.00 |
More Fusion Antibodies PLC Director Deals >Fusion Antibodies PLC News